BofA Lowers Alkermes Price Target to $33 Amid Limited Pipeline Updates

Alkermes' price target has been reduced by BofA from $35 to $33 while maintaining a Neutral rating. The firm cites minimal pipeline updates and concerns that Q2 results may not extend into 2026. Alkermes is a biotechnology company with a market capitalization of $4.45 billion and a focus on unmet medical needs. The company has strong financial health, with a net margin of 23.3% and low debt-to-equity ratio of 0.05.

Alkermes plc (ALKS), a biotechnology company specializing in unmet medical needs, has seen its price target reduced by Bank of America (BofA) from $35 to $33, while maintaining a Neutral rating. The firm cited minimal pipeline updates and concerns that the company's second-quarter (Q2) results may not extend into 2026 as the primary reasons for the adjustment [1].

In its Q2 earnings report, Alkermes reported earnings from continuing operations of 52 cents per share, which beat the Zacks Consensus Estimate of 41 cents. The company's total revenues of $390.7 million decreased 2.1% from the year-ago quarter, primarily due to lower manufacturing and royalty revenues. However, the top line comprehensively beat the Zacks Consensus Estimate of $339 million [2].

The company's strong financial health is evident, with a net margin of 23.3% and a low debt-to-equity ratio of 0.05. Alkermes' proprietary products—Vivitrol, Aristada, and Lybalvi—continue to drive sales, with the portfolio growing 14% year over year to $307.2 million in the second quarter [2].

Alkermes' pipeline remains a focus for investors. The company reported positive top-line data from the phase II Vibrance-1 study, which evaluated its investigational oral orexin 2 receptor agonist, alixorexton, for treating patients with narcolepsy type 1 (NT1). The study showed statistically significant improvements in wakefulness and cataplexy rates, leading to plans for a global phase III program [2].

Despite the positive study results, BofA's concerns about the pipeline's impact on the company's financial outlook are reflected in the reduced price target. The firm believes that the lack of significant pipeline updates and the potential for Q2 results to not extend into 2026 may limit Alkermes' growth prospects.

Investors should closely monitor Alkermes' pipeline developments and any additional earnings reports to gauge the company's performance and potential for future growth.

References:
[1] https://crypto.news/can-ethereum-reach-4000-this-week-while-ozak-ai-eyes-1-target/
[2] https://finance.yahoo.com/news/alkermes-q2-earnings-beat-estimates-142300847.html